Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05711394 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

StatusRecruiting
PhasePhase 3
SponsorAbbVie
Started2023-05-01
View on ClinicalTrials.gov ↗
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for pediatric participants. The main goal of the study is to evaluate the safety and efficacy (how well treatment works) of a low-dose and high-dose of atogepant in pediatric participants between the ages of 6 and 17. Atogepant is a medicine currently approved to treat adults with migraine (0 to 14 migraine days per month) and is being studied in pediatric participants between the ages of 6 and 17 with a history of episodic migraine. This is a Phase 3, randomized, double-blind study of atogepant in participants with a history of episodic migraine with an open-label pharmacokinetic substudy. Eligible participants will be randomized into 6 different groups. Participants between the ages of 12 and 17 will be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. Participants between the ages of 6 and 11 will also be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. The specific atogepant doses to be used in participants between the ages of 6 and 11 will be determined after the PK substudy is complete. Around 450 participants will be enrolled in approximately 100 sites worldwide. Placebo, low-dose atogepant, and high-dose atogepant are given as a tablet to take by mouth once a day. At the end of Week 12, participants will either undergo a follow-up visit 4 weeks after last study treatment or join an extension study where they can continue to receive atogepant for another 52 weeks. There may be a bigger responsibility for participants in this study. Participants will attend regular visits during the study at a hospital or clinic. The effects of treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.

Amendment record

Amended 112 times since 2023-01-26; most recent filed 2026-08-25. The 50 most recent of 113 record versions are listed below. See every version on ClinicalTrials.gov ↗

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-31.

2026-08-25
Amendment Study Status, Contacts/Locations v112
2026-08-20
Amendment Study Status, Contacts/Locations v111
2026-08-19
Amendment Study Status, Contacts/Locations v110
2026-08-13
Amendment Study Status, Contacts/Locations v109
2026-07-13
Amendment Study Status, Contacts/Locations v108
2026-06-29
Amendment Study Status, Contacts/Locations v107
2026-06-17
Amendment Study Status, Contacts/Locations v106
2026-06-10
Amendment Study Status, Contacts/Locations v105
2026-05-11
Amendment Study Status, Contacts/Locations v104
2026-03-18
Amendment Study Status, Contacts/Locations v103
2026-02-06
Amendment Study Identification, Study Status, Arms and Interventions, Outcome Measures, Contacts/Locations, IPDSharing v102
2025-07-04
Amendment Study Status, Contacts/Locations v101
2025-06-17
Amendment Study Status, Contacts/Locations v100
2025-06-05
Amendment Study Status, Contacts/Locations v99
2025-05-12
Amendment Study Status, Contacts/Locations v98
2025-04-23
Amendment Study Status, Contacts/Locations v97
2025-03-17
Amendment Study Status, Contacts/Locations v96
2025-03-06
Amendment Study Status, Contacts/Locations v95
2025-02-27
Amendment Study Status, Contacts/Locations v94
2025-02-20
Amendment Study Status, Contacts/Locations v93
2025-01-09
Amendment Study Status, Contacts/Locations v92
2024-12-20
Amendment Study Status, Contacts/Locations v91
2024-12-17
Amendment Study Status, Contacts/Locations v90
2024-11-14
Amendment Study Status, Contacts/Locations v89
2024-11-11
Amendment Study Status, Contacts/Locations v88
2024-10-31
Amendment Study Identification, Study Status v87
2024-10-11
Amendment Study Status, Contacts/Locations v86
2024-08-01
Amendment Study Status v85
2024-07-31
Amendment Study Status, Contacts/Locations v84
2024-07-30
Amendment Study Status, Study Description, Eligibility, Contacts/Locations, IPDSharing v83
2024-05-06
Amendment Study Status, Contacts/Locations v82
2024-05-01
Amendment Study Status v81
2024-04-29
Amendment Study Status v80
2024-04-26
Amendment Study Status, Contacts/Locations v79
2024-04-18
Amendment Study Status, Contacts/Locations v78
2024-04-09
Amendment Study Identification, Study Status, Contacts/Locations v77
2024-04-03
Amendment Study Status v76
2024-03-28
Amendment Study Status, Contacts/Locations v75
2024-03-27
Amendment Study Status, Contacts/Locations v74
2024-03-18
Amendment Study Status, Contacts/Locations v73
2024-03-15
Amendment Study Status, Contacts/Locations v72
2024-03-13
Amendment Study Status v71
2024-03-11
Amendment Study Status, Contacts/Locations v70
2024-03-11
Amendment Study Status, Contacts/Locations v69
2024-03-05
Amendment Study Status, Contacts/Locations v68
2024-03-01
Amendment Study Status, Contacts/Locations v67
2024-02-29
Amendment Study Status, Contacts/Locations v66
2024-02-28
Amendment Study Status, Contacts/Locations v65
2024-02-26
Amendment Study Status, Contacts/Locations v64
2024-02-20
Amendment Study Status, Contacts/Locations v63
Trial Details
NCT Number NCT05711394
Lead Sponsor AbbVie
Conditions Episodic Migraine
Enrollment 450 participants
Start Date 2023-05-01
Primary Completion 2028-03 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-09-03